|Day Low/High||307.28 / 310.37|
|52 Wk Low/High||223.02 / 333.65|
RBC Capital analysts say this would free 'trapped value' on drug treatments.
Besides Tesla, Twitter and Biogen make good candidates.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.
Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.
Biogen (NASDAQ: BIIB) today announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017.
The botox maker's CEO Bret Saunders reiterates that Allergan will be focused on smaller deals and buybacks
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Biogen (BIIB) stock is lower this afternoon after Reuters reported that the company has no plans to sell itself.
Deal rumors are deflating, but a takeover bid could reward holdouts.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
Trade-Ideas LLC identified Biogen (BIIB) as a "perilous reversal" (up big yesterday but down big today) candidate
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
Will Allergan buy Biogen? Will Merck? The rumors are pushing up Biogen's stock.
Biogen (BIIB) stock is retreating in after-hours trading on Tuesday as Allergan (AGN) reportedly is not likely to pursue a takeover bid of the company.
U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.
The companies were also the subject of merger rumors back in April.
CNBC's Meg Tirrell explained the events that led up to the takeover interest in Biogen (BIIB) today.
Trade-Ideas LLC identified Biogen (BIIB) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Biogen (BIIB) stock is spiking in late-afternoon trading on Tuesday as the company has reportedly drawn takeover interest from Merck (MRK) and Allergan (AGN).
The drug stock has soared sharply higher in recent weeks; how it behaves on a pullback will be key.
Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.
Crude oil was deadweight for Wall Street on Monday as continued worries over an international supply glut kept commodity traders bearish.
The S&P 500 and Dow Jones Industrial Average extend their declines by early afternoon Monday as crude oil prices threaten to break below $40.
TheStreet highlights 3 stocks pushing the health services industry higher today.